PA
SCLN

Perceptive Advisors’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

Perceptive Advisors’s Portfolio SCLN Stock Details SCLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-29,942
Closed -$262K – 192
2014
Q4 		$262K Buy
29,942
+13,907
+87% +$113K 0.02% 124
2014
Q3 		$110K Buy
+16,035
New +$96.1K 0.01% 114

Other funds holding SCLN

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
SI
Sensato Investors San Francisco, California $122M AUM 5.69% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return

Perceptive Advisors's SCLN Position: Q1 2015 in Review

Perceptive Advisors sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q1 2015, closing a stake of 29,942 shares — an estimated $262K sold.

Perceptive Advisors first reported a position in SCLN in Q3 2014 and held it in 2 quarters. The position peaked at $262K in Q4 2014. 130 funds tracked by Wall St. Rank hold SCLN as of Q1 2015.

  • Perceptive Advisors reported no remaining Sciclone Pharmaceuticals Inc position as of Q1 2015 after selling out during the quarter.
  • Perceptive Advisors sold 29,942 Sciclone Pharmaceuticals Inc shares in Q1 2015, an estimated $262K.
  • Perceptive Advisors first reported a position in Sciclone Pharmaceuticals Inc in Q3 2014 and held it in 2 quarters.
  • Perceptive Advisors's Sciclone Pharmaceuticals Inc position peaked at $262K in Q4 2014.
  • 130 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q1 2015.

Based on Perceptive Advisors's 13F filing for Q1 2015, filed 15 May 2015.